Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arbaclofen ER for Spasticity in Multiple Sclerosis
NCT05179577Phase 3Not yet recruiting
- Sponsor
- RVL Pharmaceuticals
- Start
- Jan 2027
- Primary completion
- Jan 2028
01
Overview
A Phase 3 trial of arbaclofen in spasticity, sponsored by RVL Pharmaceuticals. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
arbaclofen
03
Conditions
spasticity
Beyond the preview
Go deeper on NCT05179577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05179577.